

5. W1937-01

**COMBINATION OF ACTIVE PRINCIPLES, IN PARTICULAR OF
TETRAHYDROPYRIDINS AND ACETYLCHOLINESTERASE INHIBITING AGENTS,
FOR TREATING SENILE DEMENTIA SUCH AS ALZHEIMER DEMENTIA****Patent number:** WO9925363**Publication date:** 1999-05-27**Inventor:** TERRANOVA JEAN-PAUL (FR); MAFFRAND JEAN-PIERRE (FR); SOUBRIE PHILIPPE (FR)**Applicant:** TERRANOVA JEAN PAUL (FR); SANOFI SA (FR); MAFFRAND JEAN PIERRE (FR); SOUBRIE PHILIPPE (FR)**Classification:****- international:** A61K31/645; A61K31/445**- european:** A61K31/645; A61K31/445**Application number:** WO1998FR02384 19981109**Priority number(s):** FR19970014322 19971114; FR19970014324 19971114**Also published as:**EP1030671 (A1)
OA11464 (A)
CA2309966 (A1)
TR200001262T (T2)
EE4235 (B1)

more >>

Cited documents:WO9701536
US5453428
EP0458696
WO9627380
XP002074849**Abstract of WO9925363**

The invention concerns a pharmaceutical composition containing as active principles: a constituent (a) selected between 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridin and a compound (I) in which: Y represents -CH- or -N-; R1 represents hydrogen, a halogen, a hydroxyl, a CF₃, a (C3-C4)alkyl or (C1-C4)alkoxyl group; R2 represents hydrogen, a halogen, a hydroxyl, a CF₃, (C3-C4)alkyl or (C1-C4)alkoxyl group; R3 and R4 represent each hydrogen or a (C1-C4)alkyl; X represents (a) a (C3-C6)alkyl; a (C3-C6)alkoxyl; a (C3-C7)carboxyalkyl; a (C1-C4)alkoxycarbonyl(C3-C6-)alkyl; a (C3-C7)carboxyalkoxyl; or a (C1-C4)alkoxycarbonyl(C3-C6)alkoxyl; (b) a radical selected among a (C3-C7)cycloalkyl, (C3-C7)cycloalkyloxy, (C3-C7)cycloalkylmethyl, (C3-C7)cycloalkylamino and cyclohexenyl, said radical capable of being substituted by a halogen, hydroxy, (C1-C4)alkoxy, carboxy, (C1-C4)alkoxycarbonyl, amino, mono- or di-(C1-C4)alkylamino or (c) a group selected among phenyl, phenoxy, phenylamino, N-(C1-C3)alkyl-phenyl-amino, phenylmethyl, phenylethyl, p henylcarbonyl, phenylthio, phenylsulphonyl, phenylsulphinyl and styryl, said group capable of being mono- or polysubstituted on the phenyl group by a halogen, CF₃, (C1-C4)alkyl, (C1-C4)alkoxy, cyano, amino, mono- or di-(C1-C4)alkylamino, (C1-C4)acylamino, carboxy, (C1-C4)alkoxycarbonyl, aminocarbonyl, mono- or di-(C1-C4)alkylaminocarbonyl, amino(C1-C4)alkyl, hydroxy(C1-C4)alkyl, or halogeno(C1-C4)alkyl; optionally in the form of one of its pharmaceutically acceptable salts; and an constituent (b) active in the symptomatic treatment of DAT, optionally in the form of one of its pharmaceutically acceptable salts, provided that when constituent (a) is other than 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridin or one of its pharmaceutically acceptable salts, the constituent (b) is an acetylcholinesterase inhibiting agent.

Data supplied from the esp@cenet database - Worldwide